Following a very successful launch of Aptiva in 2021, Werfen EEMEA had already installed the very first unit in December 2021.
The team did not rest on their achievement after this success, but instead became even more enthused, installing another unit in January 2022.
The year 2021 ended with EEMEA winning the BIO-FLASH tender in Serbia, with the big effort of our local distributor, Makler, against a tough competition. Thanks to this, Werfen would now be able to enter the Serbian market.
On March 8, International Women's Day, the EEMEAI marketing team hosted a virtual conference to raise awareness on Bleeding and Thrombotic Disorders in Women.
O tempora, o mores! This popular exclamation used by the Latin orator Cicero fits perfectly in the present days in which our lives rapidly changed together with our habits.
Oh my gosh!!! … Those were my first words when I saw the results of a tender we had just won. I acted like my 8 and 6year old daughters on Christmas. I screamed (inside of course), jumped up and down and danced my own private victory dance. I was super happy and excited. Finland would have its first Integrated Lab in Tampere. YES!
In continuation with our "Connecting Value" meeting in April in Rome, we wanted to share amazing news regarding Hemostasis, Autoimmunity and Acute Care Diagnostics Lines and our collective ability as part of the EEMEAI world to continuously Deliver Results.
The meeting started with a focus group on Tuesday afternoon, April 9, fully dedicated to the new coming platform Aptiva®, and the whole day of Wednesday, April 10, was dedicated to Marketing updates. The success of the meeting was assured by the participation of all our partners from the EEMEAI geographies.

